Works about EMPAGLIFLOZIN
Results: 1029
The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial.
- Published in:
- BMC Endocrine Disorders, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12902-025-01882-8
- By:
- Publication type:
- Article
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice?
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 4, p. 769, doi. 10.1007/s10557-024-07598-6
- By:
- Publication type:
- Article
Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 4, p. 659, doi. 10.1007/s10557-023-07434-3
- By:
- Publication type:
- Article
Winding Down the Storm: Could Empagliflozin's Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy?
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 203, doi. 10.1007/s10557-023-07510-8
- By:
- Publication type:
- Article
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Stroke, and Mortality in Patients with Type 2 Diabetes.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 4, p. 619, doi. 10.1007/s10557-022-07374-4
- By:
- Publication type:
- Article
Empagliflozin Ameliorates Ouabain-Induced Na<sup>+</sup> and Ca<sup>2+</sup> Dysregulations in Ventricular Myocytes in an Na<sup>+</sup>-Dependent Manner.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 3, p. 461, doi. 10.1007/s10557-021-07311-x
- By:
- Publication type:
- Article
Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 4, p. 619, doi. 10.1007/s10557-021-07190-2
- By:
- Publication type:
- Article
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 6, p. 1, doi. 10.1002/dmrr.3413
- By:
- Publication type:
- Article
Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project).
- Published in:
- JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/56067
- By:
- Publication type:
- Article
Cost-effectiveness of Empagliflozin Compared to Liraglutide in Iran Based on Cardiovascular Outcome Trials in Type 2 Diabetes Mellitus.
- Published in:
- Journal of Pharmacoeconomics & Pharmaceutical Management, 2022, v. 8, n. 1, p. 24
- By:
- Publication type:
- Article
Drug delivery system for controlled release of empagliflozin from alginate-chitosan nanocarrier system.
- Published in:
- Turkish Journal of Chemistry, 2022, v. 46, n. 3, p. 805, doi. 10.55730/1300-0527.3370
- By:
- Publication type:
- Article
Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
- Published in:
- PeerJ, 2024, p. 1, doi. 10.7717/peerj.17055
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 1, p. 1, doi. 10.21542/gcsp.2023.5
- By:
- Publication type:
- Article
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
- Published in:
- Global Cardiology Science & Practice, 2021, v. 2021, n. 3, p. 1, doi. 10.21542/gcsp.2021.17
- By:
- Publication type:
- Article
Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-64175-5
- By:
- Publication type:
- Article
Effects of empagliflozin on reproductive system in men without diabetes.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-64684-3
- By:
- Publication type:
- Article
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57871-9
- By:
- Publication type:
- Article
Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse.
- Published in:
- Brain Sciences (2076-3425), 2019, v. 9, n. 3, p. 57, doi. 10.3390/brainsci9030057
- By:
- Publication type:
- Article
Renal Metabolome in Obese Mice Treated with Empagliflozin Suggests a Reduction in Cellular Respiration.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 9, p. 1176, doi. 10.3390/biom12091176
- By:
- Publication type:
- Article
Clinical effects of SGLT2 inhibitors in seven persons with HNF1A‐MODY (MODY3).
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 10, p. 1, doi. 10.1111/dme.15387
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Epigastric pain and partial ptosis.
- Published in:
- 2023
- By:
- Publication type:
- Test/Instrument
Clinical care and other categories posters: Ethnicity.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.35_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
Use of glucose‐lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose‐lowering drug groups.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 12, p. 1612, doi. 10.1111/dme.14117
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 11, p. 1494, doi. 10.1111/dme.14076
- By:
- Publication type:
- Article
Diabetes management gains: teaching old dogs new tricks.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 9, p. 1072, doi. 10.1111/dme.14068
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic profile of thesodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 8, p. 1096, doi. 10.1111/dme.13629
- By:
- Publication type:
- Article
Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2017, v. 34, n. 11, p. 1646, doi. 10.1111/dme.13508
- By:
- Publication type:
- Article
Oral Presentations.
- Published in:
- Nephrology, 2020, v. 25, p. 11, doi. 10.1111/nep.13772
- Publication type:
- Article
Mini Oral Abstracts.
- Published in:
- Nephrology, 2016, v. 21, p. 58, doi. 10.1111/nep.12887
- Publication type:
- Article
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus.
- Published in:
- Kidney & Blood Pressure Research, 2019, v. 44, n. 5, p. 984, doi. 10.1159/000501854
- By:
- Publication type:
- Article
Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway.
- Published in:
- Frontiers in Physiology, 2022, v. 13, p. 1, doi. 10.3389/fphys.2022.817542
- By:
- Publication type:
- Article
Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes.
- Published in:
- Frontiers in Physiology, 2021, v. 12, p. 1, doi. 10.3389/fphys.2021.745058
- By:
- Publication type:
- Article
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 01, doi. 10.3389/fendo.2023.1069715
- By:
- Publication type:
- Article
Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1059942
- By:
- Publication type:
- Article
Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.917761
- By:
- Publication type:
- Article
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.907984
- By:
- Publication type:
- Article
Exploring insulin alternatives: A new era in diabetes treatment.
- Published in:
- African Journal of Diabetes Medicine, 2024, v. 32, n. 5, p. 1, doi. 10.54931/AJDM-32.5.5
- By:
- Publication type:
- Article
Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study.
- Published in:
- Journal of Diabetes Investigation, 2023, v. 14, n. 3, p. 417, doi. 10.1111/jdi.13959
- By:
- Publication type:
- Article
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 5, p. 810, doi. 10.1111/jdi.13728
- By:
- Publication type:
- Article
Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 4, p. 638, doi. 10.1111/jdi.13717
- By:
- Publication type:
- Article
Commentary on Intraglumerular dysfunction predicts kidney failure in the type 2 diabetes.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 12, p. 2124, doi. 10.1111/jdi.13655
- Publication type:
- Article
Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 8, p. 1400, doi. 10.1111/jdi.13481
- By:
- Publication type:
- Article
Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 4, p. 664, doi. 10.1111/jdi.13365
- By:
- Publication type:
- Article